Alphabetical listing of all products

A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z

Prices
  • 25 mg - 88 EUR
  • 100 mg - 264 EUR
  • 250 mg - 528 EUR

Vatalanib (dihydrochloride)

Vatalanib is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, active in the submicromolar range. It also inhibits other class III kinases, such as the platelet-derived growth factor (PDGF) receptor beta tyrosine kinase, c-Kit, and c-Fms, but at higher concentrations. It is not active against kinases from other receptor families, such as epidermal growth factor receptor, fibroblast growth factor receptor-1, c-Met, and Tie-2, or intracellular kinases such as c-Src, c-Abl, and protein kinase C-alpha. Vatalanib is being developed by Bayer Schering and Novartis and currently undergoes phase III clinical trials

catalogue number: V152
synonyms: CGP-79787, PTK787, ZK222584
CAS: 212141-51-0
MW: 419.73 g/mol (dihydrochloride)

References
Cancer Res. 2000 Apr 15;60(8):2178-89. PMID: 10786682
J Med Chem. 2000 Jun 15;43(12):2310-23. PMID: 10882357